![]() All forward-looking statements in this communication reflect the Company's current views as of the date of this communication about its plans, intentions, expectations, strategies and prospects, which are based on the information currently available to it and on assumptions it has made. Statements including words or phrases such as "believe," "expect," "anticipate," "intend," "estimate," "plan," "will," "may," "look forward," "intend," "guidance," "future," "potential" or similar expressions are forward-looking statements. Sims and Cooney, any statements relating to product launch, commercialization, sales, supply or distribution, and any statements that refer to expected, estimated or anticipated future results or that do not relate solely to historical facts. Learn more at or connect with us on LinkedIn.įounded in 2013 and headquartered in Princeton, New Jersey, MAIA Pharmaceuticals is a specialty pharmaceutical company that identifies, develops, manufactures and markets innovative and niche generic products.Ĭautionary Note Regarding Forward-Looking StatementsĬertain information in this press release may be considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and any applicable Canadian securities legislation including, but not limited to, the statements by Messrs. Together, we boldly transform insights into treatments benefiting those who need them, when they need them. ![]() Our decades of proven success come from passionate team members around the globe collaborating to bring treatments forward. This may reduce waste and costs, optimize convenience and workflow and reduce the chance for preparation error-all of which support quality patient care.Įndo (OTC: ENDPQ) is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. Ready-to-use, or RTU, products streamline operations for hospitals by eliminating the need to prepare or transfer the product before patient administration. "We are pleased to partner with Endo to provide ready-to-use bivalirudin, which requires no reconstitution, no dilution and no mixing." Director, Corporate Development at MAIA Pharmaceuticals. "Like Endo, MAIA is laser-focused on delivering meaningful solutions to support healthcare providers as they deliver quality patient care," said Brian Cooney, Sr. "Through this partnership with MAIA Pharmaceuticals, we are proud to answer that call with the only ready-to-use liquid format of bivalirudin." ![]() "Hospital providers have told us what they need-ready-to-use medications that allow them to focus on patients rather than preparation," said Scott Sims, Senior Vice President and General Manager, Injectable Solutions & Generics at Endo.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |